SCHEMBL6846637

SCHEMBL6846637

Cc1cc(NC(=O)c2cccc(OC(Cl)c3cncc4ccccc34)c2)ccc1C(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.48
NPC1 O15118 7/20 0.48
POLB P06746 2/20 0.48
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
KMT2A Q03164 7/20 0.47
MEN1 O00255 6/20 0.47
BRAF P15056 2/20 0.47
CSF1R P07333 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
HSP90AA1 P07900 2/20 0.44
HSP90AB1 P08238 1/20 0.44
MMP9 P14780 2/20 0.43
MMP1 P03956 1/20 0.43
MAPT P10636 3/20 0.42
KCNK3 O14649 1/20 0.41
KCNK9 Q9NPC2 1/20 0.41
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846662 0.84 NPC1 (0.53) RAB9ANPC1POLBCASP3SENP8
SCHEMBL6845407 0.80 NPC1 (0.47) RAB9ANPC1POLBKMT2AMEN1
SCHEMBL6846851 0.78 MMP9 (0.43) RAB9ANPC1POLBCASP3SENP8
SCHEMBL6845332 0.77 CSF1R (0.44) RAB9ANPC1POLBCASP3SENP8
SCHEMBL6846634 0.77 HDAC8 (0.43) RAB9ANPC1POLBCASP3SENP7
SCHEMBL6846628 0.75 NPC1 (0.48) RAB9ANPC1POLBCASP3SENP8
SCHEMBL6846474 0.75 FGFR1 (0.41) RAB9ANPC1POLBCASP3SENP8
SCHEMBL7566711 0.73 NPC1 (0.40) RAB9ANPC1POLBCASP3SENP8
SCHEMBL6841481 0.73 KMT2A (0.57) RAB9ANPC1POLBCASP3SENP8
SCHEMBL5490431 0.73 RAB9A (0.66) RAB9ANPC1POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA RAB9A 1183/4885NPC1 4543/4885POLB 2588/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA RAB9A 1183/4885NPC1 4543/4885POLB 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.